IFNB1 and ovarian cancer: M.D. Anderson Cancer Center sponsored a phase 1 clinical trial to find the highest tolerable dose of human MSCs transfected with interferon beta (MSCs-IFNβ) that can be given to patients with ovarian cancer and to test the safety of MSCs-IFNβ.